DCAT’s Expedition Pharma: Innovation from a Patient-First Perspective

How is innovation inspiring and fueling the transformation of the bio/pharma industry? DCAT’s conference and networking event, Expedition Pharma: Innovation from a Patient-First Perspective, being held June 4–5, 2025, in Lugano, Switzerland, will provide key insights.

How is innovation inspiring and fueling the transformation of the bio/pharma industry? DCAT’s conference and networking event, Expedition Pharma: Innovation from a Patient-First Perspective, being held June 4–5, 2025, in Lugano, Switzerland, will provide key insights.

By Patricia Van Arnum, Editorial Director, DCAT, pvanarnum@dcat.org

DCAT’s European conference and networking event   
In 2024, the Drug, Chemical & Associated Technologies Association (DCAT) achieved a significant milestone in its 135-year history by hosting its first education and networking event outside the US. Responding to the needs of its diverse membership—over half of whom are headquartered outside the US—the Summit at Lugano brought together global thought leaders across all disciplines to address the topic of sustainability. This inaugural event was met with overwhelming support from all avenues of the bio/pharma industry. On the heels of that outstanding reception, DCAT will return to the picturesque city of Lugano, Switzerland, June 4-5, 2025, for its conference and networking event, Expedition Pharma: Innovation from a Patient-First Perspective.  

This unique conference and networking event aims to inspire meaningful advancements that leverage cutting-edge technology and forward-thinking strategies to enhance patient care and outcomes with patient-centric solutions. The conference will examine the most significant challenges today—from global drug shortages and supply chain disruptions to drug pricing and market access, sustainability imperatives, the influence of AI, shifting investment paradigms, and advancing technologies—all from the lens of patient impact and outcomes. The conference and networking event is an essential opportunity for C-suite executives, industry thought leaders, and decision-makers to connect, collaborate, and exchange groundbreaking strategies that align business goals with patient-centric values. 

Expedition Pharma: Innovation from a Patient-First Perspective, hosted by DCAT, will feature innovation makers from across the global bio/pharma industry to share practical and concrete ways in which their companies have worked to improve patient care and health outcomes. The two-day event will be held June 4–5, 2025, in Lugano, Switzerland. It will bring to the forefront the challenges being faced and highlight practical strategies and actions taken by bio/pharma companies and suppliers on an individual company basis and in collaboration with others.   

Expedition Pharma: Innovation from a Patient-First Perspective  is an opportunity to network with global leaders and colleagues across industry disciplines and to be a part of meaningful discussions, idea exchanges, and foster partnerships that innovate, inspire and transform from a patient-first perspective.   

Register Today – Space is Limited  
Be a part of the event that is shaping the future of the bio/pharma industry. Further information on DCAT’s Expedition Pharma: Innovation from a Patient-First Perspective may be found here

Limited presenter/panelist opportunities remain – Deadline Extended to April 11, 2025.  

DCAT Member Companies, non-members, and industry thought leaders are invited to apply to present their innovative approaches and solutions addressing one or more of the following areas:  

  • Improving product availability through mitigating drug shortages and supply-chain disruptions or enhancing production scalability;   
  • New drug pricing models and improving market access;   
  • Sustainability initiatives in R&D, manufacturing, and supply chains;  
  • Data and technology-driven solutions, such as AI or predictive analytics, to enhance R&D productivity, streamline manufacturing, or improve patient care;  
  • Advancements in quality control/assurance and safety protocols in manufacturing; and  
  • New metrics, investments, and business practices across development, manufacturing, and the supply chain, resulting in improved patient outcomes.   

Further information on DCAT’s Expedition Pharma: Innovation from a Patient-First Perspective may be found here

Recent Feature Articles

The Battle in the Obesity Drug Market Heats Up

By
Novo Nordisk’s bid to best a previous offer from Pfizer to acquire the bio/pharma company, Metsera, is the latest in the competitive obesity drug market. What are the assets the companies are vying for, and how do they stack up against other contenders in the obesity drug market?

Emerging Pharma: On the Industry’s Radar

By
Partnering deals and MA& among the large bio/pharma companies and smaller companies not only reflect strategic decisions by the bio/pharma majors to build their product portfolios, but also put these smaller companies on the industry map. Which companies are making the mark in 2025?

Executive Insights: What’s Next For Roche?

By
Roche released its earnings for the first nine months of 2025, which saw its pharmaceutical revenues increase by 9% at constant exchange rates. Its top five growth drivers – Phesgo, Xolair, Hemlibra, Vabysmo and Ocrevus – achieved total sales of nearly $20 billion. Will momentum continue?
Wave

State of the State: mRNA Product Development

By
mRNA technology was lifted into commercial success during the pandemic, with two major mRNA vaccines, Pfizer’s/BioNTech’s Comirnaty and Moderna’s Spikevax. With that market closing, where does the mRNA pipeline stand? Is oncology the next wave?